Antifungal medicine composition

A technology of antifungal drugs and compositions, applied in the field of pharmacy, can solve the problems of high recurrence rate, large toxic and side effects, etc.

Inactive Publication Date: 2009-03-18
XIANGBEI WELMAN PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although there are many types of antifungal agents, they also have the disadvantages of large toxic and side effects and high recurrence rate.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antifungal medicine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] The in vitro antibacterial effect of cyclosporin A or FK-506 and fluconazole on Trichophyton rubrum, Microsporum laniformis, Trichophyton gypsum, Epidermophyton floccus, Candida albicans

[0042] The experimental method refers to the liquid-based dilution method antifungal susceptibility test protocol published by the National Committee for Clinical Laboratory Standards (NCCLS) (National Committee for Clinical Laboratory Standards. 1998.Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi.Proposedstandard M38- P. National Committee for Clinical Laboratory Standards, Wayne, Pa.)

[0043] (1) Preparation of bacterial liquid:

[0044] Add 1ml of sterilized 0.85% normal saline to the fungal slant inoculated on the slant SDA medium, gently aspirate the mixture of spores and hyphae with a sterile dropper, count on a hemocytometer, and adjust the bacterial solution with RPMI 1640 medium Concentration to 0.4-5×10 4 CFU / ml.

[0...

Embodiment 2

[0057] In vitro antibacterial effects of cyclosporin A (CsA) or FK-506 and bifonazole on Trichophyton rubrum, Microsporum laniformis, Trichophyton gypsum, Epidermophyton flocculus, Candida albicans

[0058] The same test method as in Example 1 was used to determine the antibacterial effect, except that bifonazole was used instead of fluconazole. The results are shown in Table 2.

[0059] Table 2. Antibacterial activity (MIC μg / ml) of cyclosporine A (CsA) or FK-506 combined with bifonazole (BIF)

[0060] drug Bai Nian Red hair wool plaster Flocculent CsA >64 >64 >64 >64 >64 FK-506 >64 >64 >64 >64 >64 BIF 2.5 0.125 0.125 0.5 0.25 BIF+CsA(2μg / ml) <0.125

<0.125

<0.125

0.125 <0.125

BIF+FK-506(2μg / ml) <0.125

<0.125

<0.125

0.125 <0.125

[0061] Note: Bai Nian = Candida albicans

[0062] Red hair = Trichophyton rubrum

[0063] Wool = Microsporum laniformis

[0064] Gypsum = Trichophyton gypsum

[006...

Embodiment 3

[0067] In vitro antibacterial effect of cyclosporin A (CsA) or FK-506 and terbinafine against Trichophyton rubrum, Microsporum laniformis, Trichophyton gypsum, Epidermophyton flocculus, Candida albicans

[0068] The antibacterial effect was measured by the same test method as in Example 1, except that terbinafine was used instead of fluconazole. The results are shown in Table 3.

[0069] Table 3. Antibacterial activity of cyclosporine A (CsA) or FK-506 combined with terbinafine (MIC μg / ml)

[0070] drug Bai Nian Red hair wool plaster Flocculent CsA >64 >64 >64 >64 >64 FK-506 >64 >64 >64 >64 >64 TEB 12.5 0.0025 0.01 0.005 0.005 TEB+CsA(2μg / ml) 6.25 <0.00125

0.00125 <0.00125

<0.00125

TEB+FK-506(2μg / ml) 1.5625 <0.00125

0.0025 <0.00125

<0.00125

[0071] Note: Bai Nian = Candida albicans

[0072] Red hair = Trichophyton rubrum

[0073] Wool = Microsporum laniformis

[0074] Gypsum = Trichophyton gypsu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses one kind of antifungal medicine composition for treating superficial fungous diseases. The antifungal medicine composition contains cell synthesis factor inhibitor type immunological inhibitor; azepexole or allyl amine type antifungal agent; and pharmaceutically acceptable carrier. The immunological inhibitor and the antifungal agent account for 0.001-99.9 % of the total composition and has weight ratio of 0.01-100. The composition of the present invention may be used in treating tinea corporis, tinea capitis, tinea manuum and other superficial fungous diseases.

Description

Technical field [0001] The present invention relates to the field of pharmacology, and more specifically to an antifungal pharmaceutical composition for treating superficial mycoses. The composition contains immunosuppressive agents and antifungal agents such as azoles or allylamines. Background technique [0002] Infections caused by fungi are generally divided into two categories: superficial fungal infections and deep fungal diseases. [0003] Deep fungal infections are usually caused by Candida albicans, Cryptococcus neoformans, etc. [0004] Superficial fungal infections are usually caused by various types of ringworm, which can be divided into Trichophyton, Epidermophyton, Microsporum, etc. The main pathogenic bacteria are Trichophyton rubrum and Gypsum Trichophyton-like, Microsporum canis, Epidermophyton floccus and other superficial fungi. It often invades the skin, hair, nails, etc. The disease caused by them is called dermatophytosis, or "tinea" for short. Although Cand...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K38/13A61K9/00A61P31/10
Inventor 俞强陈嘉王希玲贺娜张怡轩戴端芳
Owner XIANGBEI WELMAN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap